Inhibrx Biosciences Inc (INBX)
15.45
-1.13
(-6.82%)
USD |
NASDAQ |
Nov 13, 16:00
15.56
+0.10
(+0.68%)
After-Hours: 20:00
Inhibrx Biosciences Debt to Equity Ratio: 0.00 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2024
--
Maximum
Mar 2024
--
Average
--
Median
Mar 2024
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.4322 |
| IGC Pharma Inc | 0.0173 |
| NovaBay Pharmaceuticals Inc | -1.128 |
| Protalix BioTherapeutics Inc | 0.7145 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 258.42M |
| Total Liabilities (Quarterly) | 39.05M |
| Shareholders Equity (Quarterly) | 219.37M |
| Current Ratio | 6.198 |